PMID- 36227462
OWN - NLM
STAT- MEDLINE
DCOM- 20221220
LR  - 20230321
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 35
IP  - 12
DP  - 2022 Dec
TI  - Dupilumab dose spacing after initial successful treatment or adverse events in 
      adult patients with atopic dermatitis: A retrospective analysis.
PG  - e15933
LID - 10.1111/dth.15933 [doi]
AB  - Strategies on long-term management of patients affected by atopic dermatitis (AD) 
      undergoing treatment with dupilumab achieving good clinical response (GCR) or 
      experiencing dupilumab-related adverse events (AEs) are scant. Data of patients 
      who implemented longer than scheduled dupilumab dosing interval due to GCR (at 
      least 52 weeks of treatment and controlled AD activity [Eczema Area Severity 
      Index </=7 and Dermatology Life Quality Index </=5 for at least 6 months]) or AEs 
      (dupilumab-related and treatment-resistant conjunctivitis) were retrospectively 
      collected. Dupilumab was tapered to Q3W or Q4W based on physician-patient shared 
      decision. At baseline (T0) and each follow-up (week 16 [T1] and week 32 [T2]) 
      disease severity was assessed. A total of 59 patients implemented longer than 
      scheduled dosing interval (44 GCR, 15 AEs). Among these, 50 (35 GCR and 15 
      conjunctivitis) patients switched to 300 mg Q3W, while nine GCR subjects to Q4W. 
      In the GCR group Q3W, 34 and 31 patients maintained clinical response at T1 and 
      T2, whereas eight and seven Q4W subjects maintained clinical response at the same 
      timepoints, respectively. No significant differences in AD severity were observed 
      between T1 and T2 in both groups. Contrariwise, one Q3W and one Q4W patients at 
      T1, and three Q3W and one Q4W subjects at T2, returned to dupilumab labeled 
      dosage due to AD worsening. In conjunctivitis group, dupilumab Q3W was maintained 
      in eight and four patients at T1 and T2, respectively. Three patients at T1 and 
      three at T2 subjects returned to the labeled interval due to conjunctivitis 
      remission. Four patients at T1 and four subjects at T2 interrupted dupilumab due 
      to the persistence of conjunctivitis. A longer dupilumab dosing interval may be a 
      valuable option in patients with a GCR and may be a useful strategy to reduce 
      treatment-related conjunctivitis, also with pharmacoeconomic benefit.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Patruno, Cataldo
AU  - Patruno C
AD  - Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, 
      Italy.
FAU - Potestio, Luca
AU  - Potestio L
AUID- ORCID: 0000-0001-5940-0592
AD  - Section of Dermatology - Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Naples, Italy.
FAU - Fabbrocini, Gabriella
AU  - Fabbrocini G
AUID- ORCID: 0000-0002-0064-1874
AD  - Section of Dermatology - Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Naples, Italy.
FAU - Napolitano, Maddalena
AU  - Napolitano M
AUID- ORCID: 0000-0003-3309-8190
AD  - Department of Medicine and Health Sciences Vincenzo Tiberio, University of 
      Molise, Campobasso, Italy.
LA  - eng
PT  - Journal Article
DEP - 20221021
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 420K487FSG (dupilumab)
SB  - IM
MH  - Humans
MH  - Adult
MH  - *Dermatitis, Atopic/diagnosis/drug therapy
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - *Conjunctivitis/chemically induced/diagnosis/drug therapy
OTO - NOTNLM
OT  - atopic dermatitis
OT  - dose spacing
OT  - dupilumab
OT  - long-term treatment
EDAT- 2022/10/14 06:00
MHDA- 2022/12/21 06:00
CRDT- 2022/10/13 11:21
PHST- 2022/08/27 00:00 [received]
PHST- 2022/10/12 00:00 [accepted]
PHST- 2022/10/14 06:00 [pubmed]
PHST- 2022/12/21 06:00 [medline]
PHST- 2022/10/13 11:21 [entrez]
AID - 10.1111/dth.15933 [doi]
PST - ppublish
SO  - Dermatol Ther. 2022 Dec;35(12):e15933. doi: 10.1111/dth.15933. Epub 2022 Oct 21.